Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin
暂无分享,去创建一个
L. Rice | Giuseppina Stifano | R. Lafyatis | B. Kahaleh | Sokratis A. Apostolidis | T. Tabib | S. Apostolidis | C. Morse
[1] D. Solter,et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice , 2017, Science.
[2] R. Glen,et al. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension , 2017, Circulation.
[3] M. Manetti,et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis , 2017, Annals of the rheumatic diseases.
[4] L. Rice,et al. Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. , 2016, The American journal of pathology.
[5] C. Shu,et al. The heparan sulphate deficient Hspg2 exon 3 null mouse displays reduced deposition of TGF-β1 in skin compared to C57BL/6 wild type mice , 2016, Journal of Molecular Histology.
[6] M. Capobianchi,et al. Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution , 2016, PloS one.
[7] Liang Tang,et al. Apelin/APJ signaling promotes hypoxia-induced proliferation of endothelial progenitor cells via phosphoinositide-3 kinase/Akt signaling. , 2015, Molecular medicine reports.
[8] M. Whitfield,et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. , 2015, The Journal of clinical investigation.
[9] B. Kahaleh,et al. Endothelial dysfunction in systemic sclerosis , 2014, Current opinion in rheumatology.
[10] A. Regev,et al. Preparation of Single‐Cell RNA‐Seq Libraries for Next Generation Sequencing , 2014, Current protocols in molecular biology.
[11] M. Farach-Carson,et al. Transcriptional Activation by NFκB Increases Perlecan/HSPG2 Expression in the Desmoplastic Prostate Tumor Microenvironment , 2014, Journal of cellular biochemistry.
[12] M. Kuwana,et al. Brief Report: Impaired In Vivo Neovascularization Capacity of Endothelial Progenitor Cells in Patients With Systemic Sclerosis , 2014, Arthritis & rheumatology.
[13] L. Joosten,et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. , 2014, The New England journal of medicine.
[14] Åsa K. Björklund,et al. Full-length RNA-seq from single cells using Smart-seq2 , 2014, Nature Protocols.
[15] Jing Tian,et al. ELABELA: a hormone essential for heart development signals via the apelin receptor. , 2013, Developmental cell.
[16] M. Matucci-Cerinic,et al. Review: evidence that systemic sclerosis is a vascular disease. , 2013, Arthritis and rheumatism.
[17] T. Quertermous,et al. Apelin-APJ Signaling Is a Critical Regulator of Endothelial MEF2 Activation in Cardiovascular Development , 2013, Circulation research.
[18] Y. Yoshioka,et al. Inhibition of apelin expression switches endothelial cells from proliferative to mature state in pathological retinal angiogenesis , 2013, Angiogenesis.
[19] Y. Tada,et al. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. , 2013, Rheumatology.
[20] Cole Trapnell,et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.
[21] Y. Tada,et al. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[22] H. Kidoya,et al. Biology of the apelin-APJ axis in vascular formation. , 2012, Journal of biochemistry.
[23] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[24] M. Manetti,et al. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. , 2011, Trends in cardiovascular medicine.
[25] S. Jimenez,et al. Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. , 2011, Arthritis and rheumatism.
[26] R. Giacomelli,et al. Cellular players in angiogenesis during the course of systemic sclerosis. , 2011, Autoimmunity reviews.
[27] M. Conforti,et al. Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis , 2011, Circulation research.
[28] O. Hilberg,et al. Apelin and pulmonary hypertension , 2011, Pulmonary circulation.
[29] Yunliang Chen,et al. Thrombospondin 1 is a key mediator of transforming growth factor β-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism , 2011, Fibrogenesis & tissue repair.
[30] Sarah A. Pendergrass,et al. Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury , 2010, PloS one.
[31] T. Kawabe,et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. , 2010, American journal of respiratory cell and molecular biology.
[32] R. Lafyatis,et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. , 2010, Arthritis and rheumatism.
[33] F. Wigley,et al. Vascular Disease in Scleroderma , 2009, Clinical reviews in allergy & immunology.
[34] S. Pendergrass,et al. Correction: Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin , 2008, PLoS ONE.
[35] M. Eyries,et al. Hypoxia-Induced Apelin Expression Regulates Endothelial Cell Proliferation and Regenerative Angiogenesis , 2008, Circulation research.
[36] B. Kahaleh. Vascular disease in scleroderma: mechanisms of vascular injury. , 2008, Rheumatic diseases clinics of North America.
[37] P. Krieg,et al. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. , 2006, Developmental biology.
[38] M. Mayes,et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. , 2006, Arthritis and rheumatism.
[39] N. Zvaifler. Relevance of the stroma and epithelial-mesenchymal transition (EMT) for the rheumatic diseases , 2006, Arthritis research & therapy.
[40] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] A. Sasseville,et al. Novel Fibrogenic Pathways Are Activated in Response to Endothelial Apoptosis: Implications in the Pathophysiology of Systemic Sclerosis1 , 2005, The Journal of Immunology.
[42] M. Jinnin,et al. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. , 2005, The American journal of pathology.
[43] S. Hinuma,et al. Apelin is a novel angiogenic factor in retinal endothelial cells. , 2004, Biochemical and biophysical research communications.
[44] Yihai Cao,et al. Impaired Angiogenesis, Delayed Wound Healing and Retarded Tumor Growth in Perlecan Heparan Sulfate-Deficient Mice , 2004, Cancer Research.
[45] David Botstein,et al. Systemic and cell type-specific gene expression patterns in scleroderma skin , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[46] R. Macko,et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. , 2002, The Journal of rheumatology.
[47] C. Wollheim,et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma) , 2001, Arthritis research.
[48] V. Rajkumar,et al. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. , 1999, Arthritis and rheumatism.
[49] M. Nugent,et al. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. , 1998, The Journal of clinical investigation.
[50] P. Emery,et al. von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. , 1997, British journal of biomedical science.
[51] J. Uitto,et al. Structural and Functional Characterization of the Human Perlecan Gene Promoter , 1997, The Journal of Biological Chemistry.
[52] I. Kovalszky,et al. Expression of extracellular matrix proteoglycans perlecan and decorin in carbon-tetrachloride-injured rat liver and in isolated liver cells. , 1996, The American journal of pathology.
[53] A. Blann,et al. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. , 1996, Annals of the rheumatic diseases.
[54] M. Karasek,et al. A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin , 1995, In Vitro Cellular & Developmental Biology - Animal.
[55] D. Noonan,et al. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. , 1991, The Journal of biological chemistry.
[56] T. Medsger,et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.
[57] M. Kahaleh,et al. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. , 1981, Annals of internal medicine.
[58] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[59] W. L. Norton,et al. Vascular disease in progressive systemic sclerosis (scleroderma). , 1970, Annals of internal medicine.
[60] J. Fries,et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. , 1969, The American journal of medicine.
[61] E. Giannoni,et al. Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition. , 2013, Arthritis and rheumatism.
[62] J. Greenwood,et al. Apelin is required for non-neovascular remodeling in the retina. , 2012, The American journal of pathology.
[63] A Sulli,et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. , 2000, The Journal of rheumatology.
[64] P. Lachenbruch,et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. , 1998, The Journal of rheumatology.